A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome
暂无分享,去创建一个
C. Foppa | A. Galli | H. Hasson | G. Morsica | S. Bagaglio | E. Messina | L. Peano | Riccardo Vercesi
[1] C. Lumbreras,et al. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection , 2019, European Journal of Clinical Microbiology & Infectious Diseases.
[2] F. Ceccherini‐Silberstein,et al. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1–4 in Italy , 2018, Scientific Reports.
[3] Francesca Ceccherini-Silberstein,et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. , 2018, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[4] V. Cuervas-Mons,et al. Baseline NS5A resistance associated substitutions may impair DAA response in real‐world hepatitis C patients , 2018, Journal of medical virology.
[5] K. Chayama,et al. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan , 2017, Antimicrobial Agents and Chemotherapy.
[6] H. Mo,et al. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. , 2017, Journal of hepatology.
[7] G. Lauer,et al. Analysis of resistance‐associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents , 2017, Journal of viral hepatitis.
[8] H. Mo,et al. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. , 2016, Gastroenterology.
[9] A. Calcagno,et al. HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing , 2016, Infection.
[10] V. Soriano,et al. Hepatitis C virus resistance to the new direct-acting antivirals , 2016, Expert opinion on drug metabolism & toxicology.
[11] H. Mo,et al. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein , 2016, Antimicrobial Agents and Chemotherapy.
[12] P. Hu,et al. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data , 2016, Scientific Reports.
[13] Christoph Sarrazin,et al. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. , 2016, Journal of hepatology.
[14] M. Carr,et al. Baseline Prevalence and Emergence of Protease Inhibitor Resistance Mutations following Treatment in Chronic HCV Genotype-1-Infected Individuals , 2015, Antiviral therapy.
[15] Tara L. Kieffer,et al. Hepatitis C virus drug resistance–associated substitutions: State of the art summary , 2015, Hepatology.
[16] F. Mcphee,et al. NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection , 2015, The Journal of infectious diseases.
[17] R. Kaiser,et al. Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors , 2015, Open forum infectious diseases.
[18] D. Webster,et al. Baseline drug Resistance Mutations are Detectable in HCV Genes NS3 and NS5A but not NS5B in Acute and Chronic HIV-Coinfected Patients , 2014, Antiviral therapy.
[19] H. Walter,et al. Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV/HCV co-infected patients in a Berlin laboratory , 2014, Journal of the International AIDS Society.
[20] Xin Huang,et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in Humans: In Vitro and In Vivo Correlations , 2011, Hepatology.
[21] P. Colson,et al. Two years' persistence of naturally present substitution R155K within hepatitis C virus NS3 protease in the absence of protease inhibitor-based therapy. , 2011, The Journal of infectious diseases.